Enter inventor name

John F Poletto

This inventor holds 39 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignee: American Cyanamid Company. Active years: 1976-1990.

USPTO Granted Patents = 39

% Patents Active = 100.0

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 132(Granted Patents)

Location History:

Nanuet, NY (US) (1976 - 1984)
Bergen, NJ (US) (1989)
Westwood, NJ (US) (1986 - 1990)

Company Filing History:

39 out of 3,580

American Cyanamid Company

patents

Years Active: 1976-1990

Loading Chart...

Areas of Expertise:

Quinolinecarboxylic Acids

Dental Antiplaque Agents

Prostanoic Acids

Epoxycyclopentanones

Naphthalenesulfonic Acids

Oxalylamides

Hydroxy Substituted Acids

Anionic Compounds

Alkoximino Compounds

Triphenylmethoxy Compounds

Amide Derivatives

Carboxyalkyl Derivatives

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4968702 - Substituted quinolinecarboxylic acids (1990-11-06),

2. 4847381 - 2-Phenyl-4-quinoline carboxylic acids (1989-07-11),

3. 4599204 - Oxalylamides useful as dental antiplaque agents and inhibitors of (1986-07-08),

4. H000083 - Dental antiplaque agents and inhibitors of connective tissue destruction (1986-06-30),

5. 4439365 - Novel hydroxy substituted prostanoic acids, esters, congeners, (1984-03-27),

6. 4387059 - Ureylenebis substituted (or unsubstituted) phenylene-carbonyl (or (1983-06-07),

7. 4343949 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1982-08-10),

8. 4342753 - Carboxyalkyl derivatives of rutin poly(H-)sulfate (1982-08-03),

9. 4342752 - Carbalkoxymethyl derivatives of rutin poly(H-)sulfate and method of use (1982-08-03),

10. 4293704 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1981-10-06),

11. 4282375 - Halogenated-naphthalenetriyltris(sulfonylimino)-aryl multicarboxylic (1981-08-04),

12. 4265829 - Halogenated-naphthalenetriyltris(sulfonylimino)-aryl disulfonic acids (1981-05-05),

13. 4237316 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1980-12-02),

14. 4231958 - Ureylene phenylene anionic naphthalenesulfonic acids (1980-11-04),

15. 4229372 - Ureylene phenylene anionic naphthalenesulfonic acids (1980-10-21),

Title: Innovator Spotlight: John F Poletto - Pioneering Arthritis Treatment.

Introduction:

John F Poletto, a proficient inventor based in Nanuet, NY (US), has made significant contributions to the medical field with his groundbreaking innovations. With an impressive portfolio of 39 patents, Poletto's work has revolutionized arthritis treatment, offering hope to many individuals suffering from this debilitating condition.

Latest Patents:

Poletto's latest patents include Substituted Quinolinecarboxylic Acids and 2-Phenyl-4-Quinoline Carboxylic Acids. These compounds have shown promise in treating arthritis by impeding progressive joint deterioration and inducing immunosuppression. The innovative methods of synthesis and application of these novel compounds mark a significant advancement in the fight against arthritic diseases.

Career Highlights:

Holding a key position at the American Cyanamid Company, John F Poletto has played a pivotal role in driving forward research and development in the pharmaceutical industry. His relentless pursuit of innovative solutions has garnered him recognition as a leading figure in the field of arthritis treatment.

Collaborations:

Poletto's collaborative efforts with esteemed colleagues, such as Seymour Bernstein and Karel F Bernady, have further enriched his innovative endeavors. By combining their expertise and knowledge, they have propelled groundbreaking research projects that have the potential to transform the landscape of arthritis treatment.

Conclusion:

In conclusion, John F Poletto stands as a visionary inventor whose pioneering work in developing novel compounds for arthritis treatment exemplifies the power of innovation in healthcare. His dedication to research, coupled with his collaborative spirit, has positioned him as a driving force in the pursuit of advancements that promise relief and improved quality of life for individuals battling arthritis.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]